drugset / Trial / NCT02402530
Efficacy and Safety of Intravenous Neridronic Acid in CRPS-I
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This clinical trial is being conducted to demonstrate the efficacy of neridronic acid in the treatment of pain associated with complex regional pain syndrome type I (CRPS-I). The trial is divided into 3 periods: a 60-day enrollment period, a 12-week trial period, and an extended follow-up period with visits at Month 6, Month 9, and Month 12. The extended follow-up period will be terminated for all participants after the last participant enrolled completes their Month 6 visit (Visit 9). The double-blind will be maintained throughout the 12-week trial period and extended follow-up period.
Timeline
- Start
- 2015-04
- Primary completion
- 2016-08
- Completion
- 2016-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Neridronic acid | Unknown | 62.5 mg | Intravenous |